Anavex Life Sciences Corp.
AVXL· Nasdaq
AVXLAnavex Life Sciences Corp.
Filed May 13, 2021 · 10-Q · 43 days after period end · 0001731122-21-000829
| Metric | Q2 2021 | Q2 2020 | Q2 2019 | Q2 2018 |
|---|---|---|---|---|
| Net Income | -$8.16M | -$7.24M | -$7.25M | -$4.75M |
| EPS Diluted | -$0.12 | -$0.12 | -$0.15 | -$0.11 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Anavex Life Sciences Corp. · CIK 1314052 · Engraved from SEC EDGAR
ended Mar 31, 2021 · filed May 13, 2021 · 43 d after period end
